The UCLA Vine Street Clinic (UVSC) was established in 2005 in order to study the diffusion of HIV among methamphetamine user networks. Since that time, it has served as a site for clinical trials, behavioral research, and direct services focusing on the treatment of addiction, HIV prevention, and the intersection of the two. It is unique in its location, bringing the best in academia from UCLA into a transitional neighborhood of predominately working poor, an area designated as a medically underserved. The facility includes exam and counseling rooms for patient care, a lab for collection and storage of biological samples, and group meeting space. Current services available at the clinic are detailed below.
For more information or to schedule an appointment, call us at (866) 449-UCLA or email us at firstname.lastname@example.org.
Our Current Programs Include:
MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE) — (The M Study)
The goal of this project is to assemble a cohort of minority men who have sex with men (MMSM) who actively use substances and engage transmission risks. This will facilitate studies on interactions between substance use and HIV progression and/or transmission. This important cohort of MMSM will characterize: (i) effects substance use on risk behaviors, and network dynamics in exposed and infected MMSM on acquisition of HIV and other sexually transmitted infections (STIs: gonorrhea, Chlamydia, syphilis, Hepatitis C (HCV)); and (ii) the extent to which substance use in MMSM facilitates behaviors that transmit HIV compared to non-drug using MMSM.
HPTN 085: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection (AMP)
This study will evaluate the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in healthy adults at high risk of HIV infection. This is also known as the AMP study (Antibody Mediated Prevention). Participants will be men who have sex with men (MSM) and transgender individuals. They will receive an IV infusion of the antibody or a placebo every 8 weeks for approximately two years. Additional study visits will be required in between infusions. All study visits will include blood collection and HIV testing and counseling.
The LA PrEP Stories Project
The goal of the LA PrEP Stories Project is to learn about the experiences of men and trans women who have sex with men and who ARE using Pre-Exposure Prophylaxis (PrEP) for HIV prevention. With this information, we plan to create programs to help improve the experiences of people who may choose to use PrEP in the future. For more information, visit https://www.facebook.com/pg/LAPrEPStories/about/
HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis (PrEP) in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW). HPTN 083 will enroll approximately 4500 HIV-uninfected MSM and TGW at risk for acquiring HIV infection, ages 18 or older at sites in the Americas, Asia and South Africa.